Inhibition of Respiration in a Flagellate Protozoon by Hypocholesterolemic Drugs

Nature ◽  
1964 ◽  
Vol 202 (4939) ◽  
pp. 1355-1355 ◽  
Author(s):  
S. AARONSON
Keyword(s):  
Hypocholesterolemic Drugs

Effect of Three Fibrate Derivatives and of Two HMG-CoA Reductase Inhibitors on Plasma Fibrinogen Level in Patients with Primary Hypercholesterolemia

1993 ◽  
Vol 70 (02) ◽  
pp. 241-243 ◽  
Author(s):  
Adriana Branchi ◽  
Angelo Rovellini ◽  
Domenico Sommariva ◽  
Angelo G Gugliandolo ◽  
Angelo Fasoli
Keyword(s):  
Slow Release ◽  
Fibrinogen Level ◽  
Plasma Fibrinogen ◽  
Fibrinogen Concentration ◽  
Plasma Fibrinogen Level ◽  
Primary Hypercholesterolemia ◽  
Reductase Inhibitors ◽  
Hmg Coa Reductase Inhibitors ◽  
Coa Reductase ◽  
Hypocholesterolemic Drugs

SummaryIn order to evaluate the effects of hypocholesterolemic drugs on plasma fibrinogen concentration, six groups of subjects with primary hypercholesterolemia have been put on treatment with diet alone or diet plus fenofibrate (100 mg t.i.d.), slow release bezafibrate (400 mg once a day), gemfibrozil (600 mg b.i.d.), simvastatin (20 mg once a day) or pravastatin (20 mg once a day) respectively. After 1 month of therapy, plasma fibrinogen significantly decreased by 9% and 15% in fenofibrate and bezafibrate groups respectively and increased by 19% in gemfibrozil treated patients. After 4 months of therapy the changes were −16% with fenofibrate, −10% with bezafibrate and +20% with gemfibrozil. No significant changes were observed in patients treated with diet alone, simvastatin or pravastatin. The fibrinogen lowering effect of fenofibrate and bezafibrate does not seem to be related to the hypolipidemic activity of the drugs.

The effect of hypocholesterolemic drugs on adrenal corticosteroid secretion

Steroids ◽  
1967 ◽  
Vol 9 (1) ◽  
pp. 41-51 ◽  
Author(s):  
David H. Huffman ◽  
Daniel L. Azarnoff
Keyword(s):  
Corticosteroid Secretion ◽  
Hypocholesterolemic Drugs

scholarly journals Effects of 12-months treatment with zoledronate or teriparatide on intima-media thickness of carotid artery in women with postmenopausal osteoporosis: A pilot study

2019 ◽  
Vol 33 ◽  
pp. 205873841882243 ◽  
Author(s):  
Elena Passeri ◽  
Daniela Mazzaccaro ◽  
Veronica Sansoni ◽  
Silvia Perego ◽  
Giovanni Nano ◽  
...  
Keyword(s):  
Subclinical Atherosclerosis ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Intima Media Thickness ◽  
Carotid Intima Media Thickness ◽  
Media Thickness ◽  
Cholesterol Levels ◽  
Median Serum ◽  
Hypocholesterolemic Drugs

Atherosclerosis and osteoporosis are interrelated entities and share similar pathogenic mechanisms. Recent studies showed that key proteins of bone metabolism, such as osteoprotegerin (OPG) and osteopontin (OPN), are also involved in vascular atherosclerosis and calcifications. The carotid intima-media thickness (CA-IMT) is an early quantitative marker of generalized atherosclerosis. Aim of study was to investigate whether 12-months treatment with zoledronate (ZLN) or teriparatide (TPT) affects CA-IMT and circulating OPG and OPN levels. In this study, 11 postmenopausal osteoporotic women (aged 73, 70.5–74.5 years; median, range interquartile) treated with 5 mg/year iv ZLN; 9 postmenopausal osteoporotic women (aged 70, 62.5–73.5 years) treated with 20 µg/day sc TPT; and 10 aged-, body mass index (BMI)-, glycemic, and lipid profiles-matched, free from anti-osteoporotic and hypocholesterolemic drugs, controls were prospectively investigated at baseline and after 12 months. At baseline, median CA-IMT was similar in the three groups and increased after 12 months. CA-IMT increased significantly in TPT-treated patients (1.0, 0.8–1.2 vs 1.1, 0.9–15 mm, P = 0.04), though the change was minimal. After 12 months of treatment, CA-IMT positively correlated with alkaline phosphatase (ALP) levels (r = 0.767, P = 0.008) and negatively with high-density lipoprotein (HDL) cholesterol levels (r = −0.65, P = 0.03), suggesting interplay between active bone remodeling and lipid profile. At baseline and after 12 months, median serum OPG and OPN levels did not differ among the groups and did not correlate with changes in CA-IMT. In conclusion, ZLN and TPT treatments are safe on carotid walls in osteoporotic women with subclinical atherosclerosis; circulating OPG and OPN are not affected by long-term anti-osteoporotic treatments and do not correlate with CA-IMT.

Sign in / Sign up

Export Citation Format

Share Document